Jeffrey Dierks Sells 13,125 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) insider Jeffrey Dierks sold 13,125 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $37.31, for a total value of $489,693.75. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Jeffrey Dierks also recently made the following trade(s):

• On Monday, January 27th, Jeffrey Dierks sold 1,629 shares of Harmony Biosciences stock. The stock was sold at an average price of $38.02, for a total value of $61,934.58.
• On Tuesday, January 21st, Jeffrey Dierks sold 1,123 shares of Harmony Biosciences stock. The stock was sold at an average price of $40.00, for a total value of $44,920.00.
• On Wednesday, January 15th, Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock. The stock was sold at an average price of $37.01, for a total transaction of $388,864.07.

Harmony Biosciences Price Performance

Shares of NASDAQ HRMY traded down $0.82 during midday trading on Friday, reaching $38.72. The company's stock had a trading volume of 274,698 shares, compared to its average volume of 549,018. The business's 50 day moving average price is $35.20 and its two-hundred day moving average price is $35.22. The company has a market cap of $2.21 billion, a P/E ratio of 18.33, a P/E/G ratio of 0.51 and a beta of 0.78. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $28.14 and a fifty-two week high of $41.61.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.15. The business had revenue of $186.00 million during the quarter, compared to analysts' expectations of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. Harmony Biosciences's revenue was up 16.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.63 earnings per share. On average, analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Institutional Trading of Harmony Biosciences

Several large investors have recently made changes to their positions in the company. Principal Financial Group Inc. lifted its stake in Harmony Biosciences by 28.4% in the 4th quarter. Principal Financial Group Inc. now owns 208,663 shares of the company's stock valued at $7,180,000 after purchasing an additional 46,194 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Harmony Biosciences by 18.0% in the fourth quarter. Rhumbline Advisers now owns 108,588 shares of the company's stock worth $3,736,000 after acquiring an additional 16,537 shares during the period. New York State Teachers Retirement System boosted its holdings in Harmony Biosciences by 2.6% in the fourth quarter. New York State Teachers Retirement System now owns 31,693 shares of the company's stock valued at $1,091,000 after acquiring an additional 809 shares during the last quarter. Legato Capital Management LLC increased its position in Harmony Biosciences by 26.0% during the 4th quarter. Legato Capital Management LLC now owns 26,720 shares of the company's stock valued at $919,000 after purchasing an additional 5,506 shares during the period. Finally, Louisiana State Employees Retirement System lifted its position in shares of Harmony Biosciences by 26.7% in the 4th quarter. Louisiana State Employees Retirement System now owns 18,500 shares of the company's stock worth $637,000 after purchasing an additional 3,900 shares during the period. Institutional investors and hedge funds own 86.23% of the company's stock.

Analysts Set New Price Targets

Several analysts recently commented on the company. Raymond James reaffirmed an "outperform" rating and set a $40.00 price objective on shares of Harmony Biosciences in a research note on Thursday, October 10th. Needham & Company LLC reaffirmed a "buy" rating and issued a $52.00 target price on shares of Harmony Biosciences in a research report on Monday, January 13th. HC Wainwright reissued a "buy" rating and set a $75.00 price target on shares of Harmony Biosciences in a research report on Monday. Mizuho lifted their target price on Harmony Biosciences from $42.00 to $52.00 and gave the company an "outperform" rating in a research report on Thursday, October 10th. Finally, Oppenheimer reissued an "outperform" rating and set a $59.00 price target (up from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Harmony Biosciences has a consensus rating of "Buy" and an average price target of $55.00.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.